Skip to content

Regeneron Pharmaceuticals

US · REGN #285 by market cap Listed 1970
920.69 -1.71 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 12:43 UTC.

FormFiledOriginal document
10-Q2026-10-30Read on SEC.gov
8-K2026-10-30Read on SEC.gov
8-K2026-10-06Read on SEC.gov
8-K2026-09-30Read on SEC.gov
10-Q2026-07-30Read on SEC.gov
8-K2026-07-30Read on SEC.gov
8-K2026-07-06Read on SEC.gov
8-K2026-06-17Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-22 04:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$14.34BAnnual2025-12-312026-02-0410-K
Net income$4.50BAnnual2025-12-312026-02-0410-K
Operating cash flow$4.98BAnnual2025-12-312026-02-0410-K
Total assets$40.56BAs of2025-12-312026-02-0410-K
Total liabilities$9.30BAs of2025-12-312026-02-0410-K
Stockholders’ equity$31.26BAs of2025-12-312026-02-0410-K
Cash and cash equivalents$3.12BAs of2025-12-312026-02-0410-K

✦ Quant Financial Health how this is computed

Good
  • Altman Z-Score is 8.44, above the 3.0 "safe zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail
  • Collaboration revenue is the largest reported line at 58.65% of revenue, across 10 reported segments.
  • EYLEA HD ® follows at 13.66%, so the top line still matters most but isn’t the whole story.

Revenue annual, last 8 years

Latest year +0.99% YoY

Margins

Gross margin
85.35%
Operating margin
25.81%
Net margin
31.41%

Key ratios & quality

PEG uses trailing P/E against the 3-year net income growth rate (1.26%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Revenue 5.15B6.56B8.50B16.07B12.17B13.12B14.20B14.34B
Gross profit 4.73B5.79B7.38B13.63B10.61B11.30B12.23B12.24B
Selling & admin expenses 1.13B1.34B1.35B1.82B2.12B2.63B2.95B2.70B
Research & development 1.47B2.45B2.74B2.86B3.59B4.44B5.13B5.85B
Operating profit 2.53B2.21B3.58B8.99B4.99B4.23B4.09B3.70B
Pretax profit 2.55B2.43B3.81B9.33B4.86B4.20B4.78B5.23B
Tax 109.10M313.30M297.20M1.25B520.40M245.70M367.30M725.80M
Net profit 2.44B2.12B3.51B8.08B4.34B3.95B4.41B4.50B
Basic EPS 2319337641374143
Diluted EPS 21.2918.4630.5271.9738.2234.7738.3441.48

Balance sheet

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Total current assets 6.45B7.69B9.78B14.01B15.88B19.48B18.66B18.02B
Cash & ST investments 2.81B3.21B3.59B5.69B7.74B10.84B9.01B8.61B
Inventory 1.15B1.42B1.92B1.95B2.40B2.58B3.09B3.20B
Total assets 11.73B14.81B17.16B25.43B29.21B33.08B37.76B40.56B
Total current liabilities 1.44B2.10B2.70B3.93B3.14B3.42B3.94B4.37B
Short-term debt ------719.70M--------
Long-term debt ----1.98B1.98B1.98B1.98B1.98B1.99B
Total liabilities 2,977,200,000.003,715,500,000.006,138,000,000.006,666,000,000.006,550,500,000.007,107,100,000.008,405,800,000.009,301,800,000.00
Total equity 8.76B11.09B11.03B18.77B22.66B25.97B29.35B31.26B
Retained earnings 5.25B7.38B10.89B18.97B23.31B27.26B31.67B35.80B

Cash flow

Line item 2018 2019 2020 2021 2022 2023 2024 2025
Operating cash flow 2.20B2.43B2.62B7.08B5.01B4.59B4.42B4.98B
Depreciation & amortization 148.20M210.30M235.90M286.20M341.40M421.00M482.90M543.70M
Free cash flow 1.81B2.00B2.00B6.53B3.40B3.67B3.54B3.77B
Dividends paid ----------00-370.30M
Stock buybacks / issuance -77.10M-252.10M-3.95B-1.01B-1.01B-1.79B-2.17B-3.33B
Ending cash balance 1.48B1.63B2.21B2.90B3.12B2.74B2.49B3.12B

Returns & efficiency

Line item 2018 2019 2020 2021 2022 2023 2024 2025
ROE % 32.8121.3231.7754.2120.9416.2615.9514.87
ROA % 23.8515.9421.9837.9115.8812.6912.4611.50
ROIC % 30.3020.1427.9445.2518.4313.1612.5411.89
5-year avg ROE % 22.6123.8726.1332.5532.2128.9027.8324.44
EBIT margin % 38.4731.2845.5158.3840.4032.5734.0536.77
FCF / sales % 27.0025.4423.5840.6327.9127.9624.9226.25
Current ratio 4.473.673.633.565.065.694.734.13
Quick ratio 3.502.862.862.984.164.823.863.28
Debt / assets 6.044.8215.7110.619.258.177.166.67
LT debt / equity 8.096.4424.4510.5511.9210.419.218.66
Interest coverage 91.5581.4367.97163.7582.8058.5287.59120.42
Revenue CAGR (3Y) % 7.8310.5013.1146.1822.9015.57-4.045.62
Net income CAGR (3Y) % 56.6433.1943.1248.9327.044.02-18.251.26
FCF CAGR (3Y) % 40.5327.1124.6553.3119.3222.33-18.473.48

Revenue breakdown most recent period

Business

Collaboration revenue58.65%
EYLEA HD ®13.66%
EYLEA ®7.81%
Libtayo ®7.74%
Other revenue6.06%
Libtayo3.01%
Praluent ®1.59%
Evkeeza ®1.08%
Lynozyfic ®0.37%

Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.

Regeneron Pharmaceuticals discussion 0 comments

Add a comment